Expanding the Use of CAR T Therapy With shRNA

Video

The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.

Celyad Oncology is targeting cancers with a number of allogeneic CAR T-cell therapies. Their lead program, CYAD-211, is currently being evaluated in the phase 1 IMMUNICY trial (NCT04613557).

Celyad presented positive interim data at the European Hematology Association (EHA) 2021 Congress in June 2021 from IMMUNICY that showed dose-dependent engraftment up to dose level 3 of 300 x 106 cells per infusion. 

The company reported that no graft-versus-host disease, dose-limiting toxicities, or CAR T-cell related encephalopathy syndromes have occurred to date. A partial response was seen in 2 of the 5 evaluable patients. CYAD-211 cells were detected by polymerase chain reaction-based methods in all 6 patients with evidence of a dose-dependent increase in cell engraftment.

GeneTherapyLive spoke with Filippo Petti, chief executive officer and chief financial officer, and Charles Morris, MBBS, chief medical officer, Celyad Oncology, about the company's future plans and upcoming research. They also discussed potential future opportunities for their short hairpin RNA platform.

REFERENCE
Celyad Oncology presents updates on allogeneic CAR T clinical candidates and shRNA-based preclinical concepts at research & development day. News release. Celyad Oncology. July 20, 2021. https://www.businesswire.com/news/home/20210720005854/en/Celyad-Oncology-Presents-Updates-on-Allogeneic-CAR-T-Clinical-Candidates-and-shRNA-based-Preclinical-Concepts-at-Research-Development-Day
Related Videos
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Michael Kelly, PhD
Related Content
© 2024 MJH Life Sciences

All rights reserved.